Paul Varki

CIK: 0001677896

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)2 (16.7%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AVTX

Avalo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

AVTX
Avalo Therapeutics, Inc.
Jun 10, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $13.10$14K
AVTX
Avalo Therapeutics, Inc.
May 21, 2026
Award(A)
Direct
24.3K shares-
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Exercise(M)
Direct
12.6K shares at avg. $8.04$101K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
37.4K shares at avg. $18.91$707K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
22.8K shares at avg. $21.22$485K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
9.3K shares at avg. $22.70$210K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
400 shares at avg. $23.71$9K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
5.2K shares at avg. $19.78$103K
AVTX
Avalo Therapeutics, Inc.
May 6, 2026
Exercise(M)
Direct
62.5K shares at avg. $13.43$839K
AVTX
Avalo Therapeutics, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
AVTX
Avalo Therapeutics, Inc.
Dec 10, 2025
Tax Payment(F)
Direct
1K shares at avg. $4.10$4K
AVTX
Avalo Therapeutics, Inc.
Jan 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	AVTX Avalo Therapeutics, Inc.	Tax Payment(F)	1,081	$13.10	$14,161	Direct
May 21, 2026	AVTX Avalo Therapeutics, Inc.	Award(A)	24,300	-	$0	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	12,563	$8.04	$101,007	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	37,375	$18.91	$706,836	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	22,839	$21.22	$484,541	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	9,253	$22.70	$210,029	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	400	$23.71	$9,484	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Sale(S)	5,196	$19.78	$102,783	Direct
May 6, 2026	AVTX Avalo Therapeutics, Inc.	Exercise(M)	62,500	$13.43	$839,375	Direct
Feb 26, 2026	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
Dec 10, 2025	AVTX Avalo Therapeutics, Inc.	Tax Payment(F)	1,016	$4.10	$4,166	Direct
Jan 28, 2025	AVTX Avalo Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct

1-12 of 12 transactions

About VARKI PAUL

VARKI PAUL (SEC CIK 0001677896) files insider reports with the SEC as Chief Legal Officer of Avalo Therapeutics, Inc. (AVTX).

Signal8 holds 6 ownership filings by VARKI PAUL, all Form 4s, filed between Jan 30, 2025 and Jun 12, 2026. Those filings report 12 transactions, from Jan 28, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on VARKI PAUL's filings is in WAYNE, PA.

Recent filings by VARKI PAUL

Jun 10, 2026: Tax withholding of AVTX shares (Form 4, code F).
May 21, 2026: Grant or award of AVTX shares (Form 4, code A).
May 6, 2026: Option exercise of AVTX shares (Form 4, code M).
May 6, 2026: Open-market sales of AVTX shares (5 lines, Form 4, code S).
May 6, 2026: Option exercise of AVTX shares (Form 4, code M).

Other insiders filing for Avalo Therapeutics, Inc. (AVTX)

Jain Rita, Director
Lind Kevin Robert, Director
Philip Ron M, Director
Sullivan Christopher Ryan, Chief Financial Officer
Doyle Mittie, Chief Medical Officer
Riley Jennifer, Chief Strategy Officer

How to read Form 4 transaction codes